Sangui - Perle im Biotechsektor bald 1ooo % ? (Seite 7949)

[fsv]

wo kaufst du sangui aktien in usa ??? barytonesax

[barytonesax]

Oh, dann bist du ja direkt angesprochen mit Sangui!
Wünsche dir eine geruhsame Nacht.
Ciao
bs

[fsv]

# barytonesax sind das aktuelle zahlen fsv

[barytonesax]

Hat sich gut gehalten bei den Amis!
Keiner gibt seine Stücke her unter 0.25 $ !
+ 25 % !!!!!!!!!!!!!!!!!!!
ciao
bs

[fsv]

ich weis stehe aber mehr auf blau ( fußball ) muß gestehen bin durch mein diabetes am abend immer sehr müde , ändert sich ein wenig durch die postinds mit dir und euch gruß an barytonesax

[barytonesax]

Morgen könnte die Post auch in Deutschland abgehn!
Hoffen wir`s!
Ciao
bs

[barytonesax]

Hallo, fsv
Das Rote ist das wesentliche!
Ciao
bs

[barytonesax]

Jawohl, und Wolf müsste auch bald hier sein!

[fsv]

danke barytonesax konnte nur das rote lesen das ander ist ausländischhh gruß nach luxenburg fsv

[barytonesax]

Form 10QSB for SANGUI BIOTECH INTERNATIONAL INC


--------------------------------------------------------------------------------

17-May-2004

Quarterly Report


ITEM 2 - MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

Forward-looking Statements

The following discussion of our financial condition and results of operationsshould be read in conjunction with the consolidated financial statements and therelated notes thereto included elsewhere in this quarterly report. Some of theinformation in this quarterly report contains forward-looking statements,including statements related to anticipated operating results, margins, growth,financial resources, capital requirements, adequacy of the Company`s financialresources, trends in spending on research and development, the development ofnew markets, the development, regulatory approval, manufacture, distribution,and commercial acceptance of new products, and future product developmentefforts. Investors are cautioned that forward-looking statements involve risksand uncertainties, which may affect our business and prospects, including butnot limited to, the Company`s expected need for additional funding and theuncertainty of receiving the additional funding, changes in economic and marketconditions, acceptance of our products by the health care and reimbursementcommunities, new development of competitive products and treatments,administrative and regulatory approval and related considerations, health carelegislation and regulation, and other factors discussed in our filings with theSecurities and Exchange Commission.


GENERAL


The Company is primarily involved in the development of artificial oxygencarriers and glucose sensors.

The Company`s clinical development projects are primarily in the preliminarystages. The Company is diligently developing several applications for itsclinical development projects, but does not anticipate beginning any governmentprotocols or clinical trials in the near term. In the course of the ongoing costcontainment efforts, these projects were halted during the last fiscal year,after having achieved the planned milestones. The Company decided to reducefurther expenditures in the blood substitute, blood additive and glucose sensorprojects to the amount necessary to find financing, industrial or distributionpartners for further development and marketing of the resulting products. TheCompany has adopted a program aimed at cost reductions and at refocusing theCompany`s funds to accelerate time to market its most promising and matureproducts.

The Company`s development projects related to cosmetic and other externalapplications of its oxygen carrier are nearing completion. In addition, theCompany holds licensing agreements with Russian manufacturers granting theCompany exclusive marketing rights for certain medical products developed orproduced in Russia. The Company has established contact with German cosmeticsvendors and other industrial partners and is planning and preparing to jointlyintroduce related products in the German and other European markets in thecourse of the current fiscal year.

As of May 4, 2004, Sangui GmbH and Mercatura Cosmetics Biotech AG ("Mercatura"),a third party entity, have signed a letter of intent aiming at marketing "PureMoisture", an anti-aging nano-formulation developed by Sangui GmbH. Under theproposed agreement, Sangui GmbH will license to Mercatura the exclusive right tosell the nano-emulsion in German and international markets.

Cost Savings

In total, management has been able to reduce the Company`s operating expenses by29% to approximately $1.2 million in the first nine months of fiscal 2004,compared to approximately $1.7 million in the respective period of last fiscalyear. General and administrative expenses have been reduced by 35% in the firstnine months of fiscal 2004 as compared to the respective period of last fiscalyear. This effort is also reflected in the net cash used in operating activitieswhich decreased 27% to approximately $1.1 million compared to approximately $1.5million net cash used in operating activities in the respective period of lastfiscal year. Management assumes that the current planning is realistic and thatthe Company`s funds and liquidity are sufficient to finance its activities atleast through the period ending September 30, 2004.





FINANCIAL POSITION


The Company`s current assets decreased approximately $1.1 million, or 57%, fromJune 30, 2003 to approximately $881,000 at March 31, 2004. The decrease isprimarily attributable to a decrease in cash and cash equivalents ofapproximately $453,000 and a decrease in available for sale securities ofapproximately $557,000. The decrease in cash and cash equivalents and availablefor sale securities results primarily from funding the current year`s operationsof the Company with no revenues in the three- and nine-month periods ended March31, 2004.

The Company`s net property and equipment decreased approximately $49,000, or 31%from June 30, 2003 to approximately $111,000 at March 31, 2004. The decrease isprimarily attributable to current year depreciation of approximately $73,000,partially offset by purchases of property and equipment of approximately$10,000.

The Company funded its operations primarily through its existing cash reserves.The Company`s stockholders` equity decreased approximately $1.1 million. Theprimary decrease is caused by the Company`s current period net loss ofapproximately $1.2 million, and an increase in accumulated other comprehensiveincome of approximately $84,000 due to foreign currency translation adjustmentsand unrealized gains on marketable securities.


RESULTS OF OPERATIONS


Three months ended March 31, 2004 and 2003:

Sangui Gmbh-RESEARCH AND DEVELOPMENT. Research and development expenses decreased 18% toapproximately $254,000 in 2004 from approximately $308,000 in 2003. The decreaseis mainly attributed to the ongoing refocusing program.

GENERAL AND ADMINISTRATIVE. General and administrative expenses decreased 55% toapproximately $115,000 in 2004 from approximately $253,000 in 2003. Thisdecrease is mainly attributed to the ongoing refocusing program.

DEPRECIATION. Depreciation decreased 88% to approximately $16,000 in 2004 fromapproximately $130,000 in 2003. This decrease is mainly attributed to theongoing restructuring of Sangui GmbH.

Sangui Biotech International, Inc.-GENERAL AND ADMINISTRATIVE. General and administrative expenses increased 122%to approximately $20,000 in 2004 from approximately $9,000 in 2003. The increaseis due to increased consulting and legal fees.

ConsolidatedNET LOSS. As a result of the above factors, the Company`s consolidated net losswas approximately $395,000, or $0.01 per common share, in 2004, compared toapproximately $662,000, or $0.02 per common share, in 2003.

Nine months ended March 31, 2004 and 2003:

Sangui Gmbh-RESEARCH AND DEVELOPMENT. Research and development expenses decreased 6% toapproximately $671,000 in 2004 from approximately $712,000 in 2003. The decreaseis mainly attributed to the ongoing refocusing program.

GENERAL AND ADMINISTRATIVE. General and administrative expenses decreased 45% toapproximately $363,000 in 2004 from approximately $655,000 in 2003. Thisdecrease is mainly attributed to the ongoing refocusing program.

DEPRECIATION. Depreciation decreased 67% to approximately $73,000 in 2004 fromapproximately $221,000 in 2003. This decrease is mainly attributed to theongoing restructuring of Sangui GmbH.




Sangui Biotech International, Inc.GENERAL AND ADMINISTRATIVE. General and administrative expenses increased 14% toapproximately $141,000 in 2004 from approximately $124,000 in 2003. The increaseis due to increased consulting and legal fees.

ConsolidatedNET LOSS. As a result of the above factors and the loss from discontinuedoperations (see Note 5), the Company`s consolidated net loss was approximately$1.2 million, or $0.03 per common share, in 2004, compared to approximately $1.7million, or $0.04 per common share, in 2003.


LIQUIDITY AND CAPITAL RESOURCES


For the nine months ended March 31, 2004, net cash used in operating activitiesdecreased to approximately $1.1 million from approximately $1.5 million in thecorresponding period in 2003, primarily related to a decrease in the Company`sconsolidated net loss as a result of the ongoing refocusing program.

For the nine months ended March 31, 2004, net cash provided by investingactivities decreased to approximately $564,000 from approximately $801,000 netcash provided by investing activities in the corresponding period in 2003. Theprincipal decrease is due to the maturity of marketable securities and purchasesof marketable securities in 2003. Additionally, the Company decreased purchasesof property and equipment during the nine months ended March 31, 2004, comparedto the corresponding period in 2003.

Working capital was approximately $816,000 at March 31, 2004, a decrease ofapproximately $1.1 million from June 30, 2003 due primarily to the Company`s netloss for the nine-month period. A substantial portion of the Company`s totalassets consists of cash and highly liquid marketable securities classified asavailable for sale securities. The highly liquid nature of these assets providesthe Company with flexibility in financing and managing its business. For thethree and nine months ended March 31, 2004, the realized loss on the Company`smarketable securities were approximately $290 and $290, respectively, andunrealized (losses) gains were approximately $(63,000) and $17,000,respectively.

At March 31, 2004, the Company had cash and liquid marketable securities ofapproximately $746,000. The Company believes that its available cash will besufficient to satisfy its requirements at least through the period endingSeptember 30, 2004. However, the Company will need substantial additionalfunding to fulfil its business plan and the Company intends to explore financingsources for its future development activities. No assurance can be given thatthese efforts will be successful.

Sieht nicht schlecht aus, haben die Kosten enorm gedrückt, Geld wird reichen bis September2004 baritonesax